IBJNews

Roche acquires Marcadia Biotech

Back to TopCommentsE-mailPrintBookmark and Share

Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by former Eli Lilly and Co. executives in 2006, has been acquired by Swiss life sciences giant Roche.

The deal closed Wednesday, confirmed Roche spokesman Geoff Teeter.

“Details of the transaction are not being disclosed at this stage," Roche said in a written statement to IBJ. "Roche will disclose more information on this transaction on publication of our full-year financial report in February.”

Roche’s holdings include Roche Diagnostics in Indianapolis, which has about 3,500 local employees.

Marcadia has about a dozen employees at its 11711 N. Meridian St. headquarters. While relatively small, the firm has raised millions in venture capital.

Marcadia’s chief scientific officer is Richard DiMarchi, who previously headed the biotechnology group at Lilly Research Labs, the research and development arm at Eli Lilly. He is also a professor and researcher at Indiana University, which has rights to some of Marcadia’s experimental drugs.

DiMarchi helped found the company with Gus Watanabe, the former head of Lilly's research laboratories and BioCrossroads chairman, who died in 2009.

Marcadia has been focusing on drugs to treat  metabolic diseases such as diabetes and obesity.

It previously partnered with drug giant Merck & Co. Inc. and with Indianapolis-based Lilly. Last June, Marcadia and Lilly struck a deal to develop short-acting glucagon drugs to treat severe hypoglycemia.

The Carmel company in 2007 raised $15 million in venture capital from Menlo Park, Calif.-based 5AM Investors, Seattle-based Frazier Healthcare Ventures and from locally based Twilight Venture Partners.

Former Twilight partner Kent Hawryluk serves as vice president of business development at Marcadia.

Marcadia’s profile has been rising, with a big external validation coming last year when results of its research on obesity-fighting compounds were published in the scientific journal Nature Chemical Biology, better known as Nature.

Marcadia’s researchers injected into mice a molecule they developed for treating obesity. The molecule decreased body weight by 25 percent and fat mass by 42 percent after one week.

“The results that we saw in these animal models were unprecedented,” Marcadia CEO Fritz French told IBJ at the time.

The promise underscored the need for hundreds of millions of dollars to proceed with human trials and eventually to bring the drug to market.

Neither French nor DiMarchi could be reached for comment Thursday.

Roche is a well-established leader in diabetes research and blood glucose monitoring devices.  Last February, the company announced progress in studies of its weekly taspoglutide drug in reducing blood glucose for those with Type 2 diabetes.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If I were a developer I would be looking at the Fountain Square and Fletcher Place neighborhoods instead of Broad Ripple. I would avoid the dysfunctional BRVA with all of their headaches. It's like deciding between a Blackberry or an iPhone 5s smartphone. BR is greatly in need of updates. It has become stale and outdated. Whereas Fountain Square, Fletcher Place and Mass Ave have become the "new" Broad Ripples. Every time I see people on the strip in BR on the weekend I want to ask them, "How is it you are not familiar with Fountain Square or Mass Ave? You have choices and you choose BR?" Long vacant storefronts like the old Scholar's Inn Bake House and ZA, both on prominent corners, hurt the village's image. Many business on the strip could use updated facades. Cigarette butt covered sidewalks and graffiti covered walls don't help either. The whole strip just looks like it needs to be power washed. I know there is more to the BRV than the 700-1100 blocks of Broad Ripple Ave, but that is what people see when they think of BR. It will always be a nice place live, but is quickly becoming a not-so-nice place to visit.

  2. I sure hope so and would gladly join a law suit against them. They flat out rob people and their little punk scam artist telephone losers actually enjoy it. I would love to run into one of them some day!!

  3. Biggest scam ever!! Took 307 out of my bank ac count. Never received a single call! They prey on new small business and flat out rob them! Do not sign up with these thieves. I filed a complaint with the ftc. I suggest doing the same ic they robbed you too.

  4. Woohoo! We're #200!!! Absolutely disgusting. Bring on the congestion. Indianapolis NEEDS it.

  5. So Westfield invested about $30M in developing Grand Park and attendance to date is good enough that local hotel can't meet the demand. Carmel invested $180M in the Palladium - which generates zero hotel demand for its casino acts. Which Mayor made the better decision?

ADVERTISEMENT